We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




GE Healthcare Completes Acquisition of Whatman

By Biotechdaily staff writers
Posted on 14 May 2008
GE Healthcare (Chalfont St. More...
Giles), a unit of General Electric Company (Fairfield, CT, USA) announced that it has completed the acquisition of Whatman PLC (Kent, UK), a global supplier of filtration products and technologies.

The acquisition expands GE Healthcare's offering for life-science research and biopharmaceutical manufacturing, a key area of growth for the company. GE Healthcare's Life Sciences business is a world-class provider of technologies for cellular and protein science research, and tools used in the manufacture of biopharmaceuticals such as vaccines, cell therapies and antibodies. The addition of Whatman's innovative filters and membranes for laboratory research, life sciences and medical technology applications will offer substantial customer benefits and create significant synergies through complementary product and service offerings.

Commenting on the close, Peter Ehrenheim, president and CEO of GE Healthcare's Life Sciences business, said, "Whatman's expertise and reputation in filtration technologies and sample preparation is a great fit for our Life Sciences business. We believe that combining the skills of the two companies will enable GE Healthcare to create strong added value for customers in biomedical and drug discovery research.”

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases, and other conditions earlier. GE Healthcare's vision for the future is to enable a new early health model of care focused on earlier diagnosis, pre-symptomatic disease detection, and disease prevention.

A global leader in filtration technology, Whatman provides innovative life science products to the scientific community. Whatman has developed total sample preparation solutions through its robust line of filtration devices and membranes. The company's breakthrough protein array technology and FTA technology to capture archive and purify DNA at room temperature, enables it to provide novel solutions for the analytical, health care, and bioscience markets.


Related Links:
GE Healthcare
Whatman

Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.